
|Articles|April 28, 2003
New BPH guidelines endorse combination drug therapy for select patients
>ChicagoCombination drug therapy for benign prostatic hyperplasiahas won the endorsement of the American Urological Association in the organization'sfirst-ever clinical guidelines for the management of BPH.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








